Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Rhea-AI Summary

Genprex (NASDAQ: GNPX) has been selected to present at the 2025 ASCO Annual Meeting in Chicago, showcasing their Acclaim-3 Phase 1/2 clinical trial design. The presentation will focus on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC).

The presentation is scheduled for May 31, 2025, from 1:30 to 4:30 p.m. CT, and will be delivered by Dr. Bo Wang from Oncology Associates of Oregon. The abstract will be featured in the Trials in Progress poster session, highlighting the company's innovative approach in cancer treatment development.

Positive

• Selection to present at prestigious ASCO Annual Meeting demonstrates industry recognition
• Advancement of innovative gene therapy treatment into Phase 1/2 clinical trials

Negative

• None.

Presentation to Highlight Genprex's Study of Reqorsa Gene Therapy in Combination with Tecentriq^® for the Treatment of Extensive Stage Small Cell Lung Cancer

AUSTIN, Texas, April 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been selected to present at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois and online. Genprex's abstract was selected for a poster presentation for the Trials in Progress portion of the conference. The Company will present the trial design of the Acclaim-3 Phase 1/2 clinical trial evaluating Genprex's lead drug candidate, Reqorsa^® Gene Therapy (quaratusugene ozeplasmid), in combination with Tecentriq^® as maintenance therapy for the treatment of extensive stage small cell lung cancer (ES-SCLC).

"We are very excited to be selected to present the design of our Acclaim-3 clinical trial at this year's annual ASCO meeting, among some of the most cutting-edge advances in oncology," said Ryan Confer, President and Chief Executive Officer at Genprex. "We look forward to presenting the trial design of Acclaim-3 to other organizations and industry leaders committed to shaping the future of cancer care."

The featured Genprex abstract to be presented at the 2025 ASCO Annual Meeting:

Title: A phase 1/2 clinical trial of quaratusugene ozeplasmid gene therapy and atezolizumab maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC)
Session Type: Poster Session
Presentation Date: Saturday, May 31, 2025
Presentation Time: 1:30 – 4:30 p.m. CT
Presenter: Bo Wang, MD, Oncology Associates of Oregon

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex^® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa^® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-selected-to-present-trial-design-of-acclaim-3-clinical-trial-evaluating-reqorsa-gene-therapy-in-small-cell-lung-cancer-at-2025-asco-annual-meeting-302435855.html

SOURCE Genprex, Inc.

FAQ

What is the purpose of Genprex's Acclaim-3 clinical trial for GNPX stock?

The Acclaim-3 trial evaluates Reqorsa Gene Therapy combined with Tecentriq as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC).

When and where will Genprex present their Acclaim-3 trial design?

Genprex will present on May 31, 2025, from 1:30-4:30 p.m. CT at the 2025 ASCO Annual Meeting in Chicago.

What phase is Genprex's Acclaim-3 trial for ES-SCLC?

The Acclaim-3 is a Phase 1/2 clinical trial.

Which drugs are being combined in Genprex's Acclaim-3 trial?

The trial combines Reqorsa Gene Therapy (quaratusugene ozeplasmid) with Tecentriq.